Nasdaq:US$13.55 (+0.20) | HKEX:HK$20.80 (+0.08) | AIM:£1.99 (-0.05)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors